No Carolina / New York / Florida        Ph: 561.316.3330

Turkish Journal of Medical Sciences Published Study Results: Cadaver Vs Simulator Based Arthroscopic Training in Shoulder Surgery

What To Know

  • The findings of a recent study strengthen the evidence base for medical establishments to rapidly transition to digital training solutions and furthermore strengthens the outlook for simulation training in a post-COVID future.
  • Even before the pandemic, each cadaver has limited use for medical training, and cadaveric training is not permitted in many other countries, there is vast potential for the growth in technology for training.

February 9, 2021

Turkish Journal of Medical Sciences Key study findings show 20% faster procedure time for simulation training, 30% less cartilage damage during simulation training, VR Simulators as effective as “gold standard” cadavers for training arthroscopic procedures.

It is estimated that 20,000 people a year in the US donate their bodies (cadavers) for scientific and medical training purposes. This has dramatically changed during COVID-19, with these types of training often canceled, understandably due to the constraints imposed to control the spread of the virus. Even before the pandemic, each cadaver has limited use for medical training, and cadaveric training is not permitted in many other countries, there is vast potential for the growth in technology for training.

Simulation training has been able to continue throughout the pandemic, and forecasts predict that there will be a further shift towards virtual and mixed reality simulators. The findings of a recent study strengthen the evidence base for medical establishments to rapidly transition to digital training solutions and furthermore strengthens the outlook for simulation training in a post-COVID future.

Modern simulators are so advanced that they can realistically simulate the key elements needed to teach a surgical procedure including representing the physical anatomy for joint manipulation and palpation, and on-demand pathologies and complications. This way physicians can repeat their training cases ad infinitum until proficiency. In addition, simulators provide quantitative and visual feedback on damage, which is not possible with cadavers.

The recent study led by Dr. Gazi Huri, the Turkish Academy of Science, Young Scientist Award Winner has highlighted the benefits of simulation training during arthroscopic shoulder surgery. Trainees, undertaking the European Orthopaedics & Traumatology Education Platform accredited Shoulder Club International Cadaver Course, performed surgery on either donated cadavers or the VirtaMed ArthroS™ simulator. The results showed that course completion was 20% quicker and that cartilage showed significantly less damage (30%) when students trained, via simulation, proving that simulator training is a competent training technology for now and the future.

In the case of the Shoulder Club International Cadaver Course, VirtaMed simulators provided trainees with visual feedback on damage caused to shoulder cartilage. Trainees were, therefore, more aware and able to adjust and improve their techniques accordingly. As a result, there was 50% more damage caused to the cartilage by residents that had only used cadaveric training.

Can simulators be the replacement for cadavers in the future? With cadaver dissections still being seen as the golden standard for surgical training, their disadvantages have been highlighted during the pandemic – lack of replicability, lack of objective training metrics, and of course the potential safety issues of close contact training.

During 2020 and into this year, simulation training continued due to its flexibility and the ability to train with added safety measures in place. The aim of this study was to research the efficiency of using medical simulators in surgical training as a replacement for cadavers. The results showed that all students, both the cadaver and simulation groups, achieved the proficiency levels required to be competent in arthroscopic shoulder surgery, yet there were further positive outcomes from those training on the ArthoS™ simulator.

Dr. Gazi Huri, Associate Professor of Orthopedics and Traumatology at Hacettepe University said, “It is obvious that precautions taken for the Covid-19 pandemic would last for a long time. This circumstance highlights the importance of less crowded, individualized educational models in the medical field. For the fields such as orthopedics where practical training and hands-on education are an essential part, Virtual Reality Simulators can be considered as the best solution.

Huri added, “As far as we know this is the first time a study of this sort has been undertaken.  With the shift to VR simulators rapidly increasing in the medical training for several procedures, we wanted to demonstrate that the shift is beneficial to the industry. According to this study, we are able to state that VR Simulators are just as effective as cadavers for training arthroscopic procedures.”

Beat Rechsteiner, Senior Director International Business at VirtaMed, commented, “Our ArthroS™ simulator is used for training throughout the world and we are convinced that it is an essential training solution, particularly under the constraints of COVID-19.  This study demonstrates that now is the time to invest in simulator training and benefit from training residents quicker, safer, and with advanced proficiency.”

Read the full study here.

Latest

Unlocking New Hope: Alzheimer’s Patients Join Amyloid-Targeting Therapy Study

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

The research, presented at the American Society of Interventional Pain Physicians (ASIPP) Annual Meeting, included a registrational Phase 3 trial and an integrated safety analysis of six clinical studies, as well as a real-world analysis of current treatment options and gaps in the clinical management of patients with newly-diagnosed LDH.

By using this website you agree to accept Medical Device News Magazine Privacy Policy